AEYE Health & Topcon Advance AI DR Screening

AEYE Health and Topcon Healthcare have unveiled promising results from a recent study evaluating Topcon’s NW500 non-mydriatic retinal camera in combination with AEYE Diagnostic Screening (AEYE-DS). The findings highlight exceptional diagnostic efficacy and imageability, reinforcing the potential of AI-driven autonomous screening for diabetic retinopathy (DR).

Key Study Findings: High Diagnostic Accuracy and Imaging Success

In the study, AEYE-DS AI technology, when integrated with the Topcon NW500, demonstrated:

• 92% sensitivity and 90% specificity, ensuring high clinical diagnostic accuracy.

• 100% imageability, with over 99% of patients successfully imaged on the first attempt without dilation.

AEYE-DS is FDA-cleared for use with Topcon’s TRC-NW400 and is available through the Harmony digital health platform. AEYE Health is now seeking additional FDA clearance to expand its autonomous screening solution to include the Topcon NW500.

Currently, AEYE-DS remains the only FDA-approved autonomous AI screening solution requiring just a single image per eye. When used with the NW500, it eliminates the need for dilation, significantly reducing screening time to under one minute.

Advancing Diabetic Retinopathy Screening with AI

The integration of AEYE-DS AI technology with Topcon’s NW500 demonstrates exceptional usability and efficiency, offering a scalable solution for diabetic retinopathy screening. With its integration into the Harmony digital health platform, the system enables:

• Efficient, real-time diagnostic screening

• Streamlined referrals for timely treatment

• Seamless deployment across diverse clinical settings

Industry Leaders Highlight the Impact of AI-Driven DR Screening

Zack Dvey-Aharon, PhD, CEO of AEYE Health, emphasized the breakthrough nature of this technology:

"This is a great day for blindness prevention, as our partnership with Topcon Healthcare continues to advance diabetic retinopathy screening using AI. With Topcon’s NW500, we achieved 100% imageability and nearly 100% first-attempt success without dilation. This ensures that all patients can be screened immediately, preventing anyone from missing this critical diagnostic opportunity. This remarkable achievement will significantly drive AI screening adoption in the US and globally."

Ali Tafreshi, CEO & President of Topcon Healthcare, also underscored the importance of this innovation in scaling diabetic retinopathy screening:

"To successfully scale diabetic retinopathy screening for all patients, high-quality robotic imaging combined with a robust AI algorithm is essential. The NW500 with AEYE-DS will empower primary care providers to enhance patient outcomes and increase adherence to diabetic retinopathy screenings. This marks another major milestone in delivering healthcare from the eye."

Transforming Diabetic Retinopathy Detection for the Future

The combination of Topcon’s NW500 and AEYE-DS AI technology represents a significant step forward in autonomous diabetic retinopathy screening, making the process more efficient, accurate, and accessible. With high diagnostic accuracy, rapid image acquisition, and the elimination of dilation, this solution has the potential to revolutionize retinal disease detection and improve patient care worldwide.